Overview

Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis

Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
A Phase I study of ExoFlo, an ex vivo culture-expanded adult allogeneic bone marrow mesenchymal stem cell derived extracellular vesicle product, for the treatment of medically refractory ulcerative colitis
Phase:
Phase 1
Details
Lead Sponsor:
Direct Biologics, LLC